Riskpilot← Back to searchSign inGet full accessAurevia AB
ABActiveOrg 5565873147Skolgatan 8Research and experimental development on natural sciences and engineering · NACE 7210Est. 200029 employees
Revenue 2024
SEK 45,3M
-5% vs 2023
EBITDA margin
7.4%
-31% vs 2023
Equity ratio
25.7%
Financial strength
Net profit 2024
SEK 2M
-43% vs 2023
| Revenue | SEK 45,3M | -5% |
| EBITDA | SEK 3,3M | -31% |
| Net profit | SEK 2M | -43% |
| Total assets | SEK 17,3M | +16% |
| Equity | SEK 4,4M | -1% |
| Employees | 29 | — |
Legal name
Aurevia AB
Org number
5565873147
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13 mars 2000
Share capital
SEK 100 000
Employees
29 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Aktiebolaget ska bedriva konsulttjänster inom läkemedelsbranschen samt utföra tjänster relaterade till forskning inom läkemedel och medicintekniska produkter, med avseende på kvalitets- och regleringsfrågor samt idka därmed förenlig verksamhet.
Address
Skolgatan 8
Email
contact@aurevia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 20 858 | 26 893 | 30 899 | 37 100 | 41 375 | 47 622 | 45 299 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | 3 054 | 1 636 | −1 276 | 1 530 | 2 480 | 6 165 | 5 360 | 4 854 | 3 335 |
| Depreciation & amort. | −84 | −95 | −120 | −145 | −105 | −97 | −85 | −59 | −37 |
| EBIT | 2 970 | 1 541 | −1 396 | 1 385 | 2 375 | 6 068 | 5 275 | 4 795 | 3 298 |
| Net financials | 49 | −167 | −51 | 7 | −24 | 13 | −4 | 28 | 56 |
| Profit before tax | 2 250 | 1 169 | 37 | 1 391 | 2 304 | 5 265 | 4 102 | 4 362 | 2 504 |
| Tax | −507 | −323 | −33 | −305 | −507 | −1 099 | −856 | −932 | −544 |
| Net profit | 1 743 | 846 | 4 | 1 086 | 1 797 | 4 166 | 3 246 | 3 430 | 1 960 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11 422 | 8 138 | 7 293 | 8 426 | 10 312 | 15 075 | 16 904 | 14 844 | 17 273 |
| Equity | 2 199 | 1 445 | 1 449 | 2 535 | 2 732 | 4 897 | 4 143 | 4 473 | 4 433 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 098 | 4 364 | 4 975 | 5 022 | 6 791 | 8 688 | 10 271 | 7 671 | 9 290 |
| Total debt | 7 098 | 4 364 | 4 975 | 5 022 | 6 791 | 8 688 | 10 271 | 7 671 | 9 290 |
EBITDA margin
7.4%
This company
15.8%
Market median
-53% vs market
20162024
Equity ratio
25.7%
This company
38.2%
Market median
-33% vs market
20162024
Return on equity
44.2%
This company
18.4%
Market median
+140% vs market
20162024
Net profit margin
4.3%
This company
8.1%
Market median
-47% vs market
20162024
Asset turnover
2.62×
This company
1.12×
Market median
+134% vs market
20162024
Debt / equity
2.90×
This company
0.62×
Market median
-368% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
IU Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
LG Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2026 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LABQUALITY OY | Company | 100.0% | 100.0% | 2025 |
U Hammarström AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LABQUALITY OY
Aurevia AB (this company)Scandinavian Cro ASSCANDINAVIAN CRO ASBoard members of Aurevia AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Inger Ulrika Alexandra Hammarström | Chief Executive Officer | 0 companies |
| Lars Gustaf Kylberg | Chief Auditor | 0 companies |
| Ulf Carl Magnus Boberg | Chairman | 0 companies |
| Juha-Pekka Nuutinen | Board of Directors | 0 companies |
| Britt Ann-Charlotte Beckman | Chairman | 0 companies |
| Ida Josefin Johansson | Deputy Board Member | 0 companies |
| Jens Mattsson | Board of Directors | 0 companies |
| Antti Tapani Ojala | Deputy Board Member | 0 companies |
| Karl Robert Mattias Bergqvist | Board of Directors | 0 companies |